Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton ...
CORAL GABLES, Fla., June 13, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that …